Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction.

PubWeight™: 2.38‹?› | Rank: Top 2%

🔗 View Article (PMID 15613941)

Published in Epidemiology on January 01, 2005

Authors

Sebastian Schneeweiss1, Robert J Glynn, Elizabeth H Tsai, Jerry Avorn, Daniel H Solomon

Author Affiliations

1: Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA. schneeweiss@post.harvard.edu

Articles citing this

Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA (2014) 4.23

Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology (2006) 3.54

Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol (2005) 3.33

Confounding control in healthcare database research: challenges and potential approaches. Med Care (2010) 3.01

ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA (2011) 2.77

Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. Am J Epidemiol (2010) 2.74

Bias modelling in evidence synthesis. J R Stat Soc Ser A Stat Soc (2009) 2.74

Performance of propensity score calibration--a simulation study. Am J Epidemiol (2007) 2.56

Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol (2005) 2.55

Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med (2012) 2.18

A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf (2010) 1.95

Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ (2006) 1.82

Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol (2011) 1.72

Instrumental variables II: instrumental variable application-in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance. J Clin Epidemiol (2009) 1.56

Adjustments for unmeasured confounders in pharmacoepidemiologic database studies using external information. Med Care (2007) 1.56

Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther (2007) 1.42

Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ (2017) 1.40

When the entire population is the sample: strengths and limitations in register-based epidemiology. Eur J Epidemiol (2014) 1.27

Assessing residual confounding of the association between antipsychotic medications and risk of death using survey data. CNS Drugs (2009) 1.02

Placebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trials. Med Care (2011) 1.00

Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum (2008) 0.91

Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur Heart J (2009) 0.89

Effect of evidence-based drug therapy on long-term outcomes in patients discharged after myocardial infarction: a nested case–control study in Italy. Pharmacoepidemiol Drug Saf (2013) 0.87

Propensity score calibration in the absence of surrogacy. Am J Epidemiol (2012) 0.86

Aspirin and non-steroidal anti-inflammatory drug use and the risk of upper aerodigestive tract cancer. Br J Cancer (2014) 0.84

Field methods in medical record abstraction: assessing the properties of comparative effectiveness estimates. BMC Health Serv Res (2014) 0.83

Use of nonsteroidal anti-inflammatory drugs and risk of oral cancer: a cohort study. Br J Cancer (2006) 0.82

Propensity Score Calibration and its Alternatives. Am J Epidemiol (2007) 0.80

Kidney function decline in metformin versus sulfonylurea initiators: assessment of time-dependent contribution of weight, blood pressure, and glycemic control. Pharmacoepidemiol Drug Saf (2013) 0.79

Rediscovering drug side effects: the impact of analytical assumptions on the detection of associations in EHR data. AMIA Jt Summits Transl Sci Proc (2015) 0.78

Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study. J Am Heart Assoc (2017) 0.76

Assessing the impact of prescribed medicines on health outcomes. Aust New Zealand Health Policy (2007) 0.75

Passive smoking and stroke in men and women: a national population-based case-control study in China. Sci Rep (2017) 0.75

Risk of gastrointestinal bleeding and cardiovascular events due to NSAIDs in the diabetic elderly population. BMJ Open Diabetes Res Care (2015) 0.75

Articles by these authors

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36

Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res (2007) 14.84

Variable selection for propensity score models. Am J Epidemiol (2006) 10.68

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52

A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol (2005) 8.77

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65

Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med (2005) 8.44

Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32

High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (2009) 7.40

A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol (2005) 7.31

Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19

Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J (2004) 6.57

Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol (2005) 6.20

Surgery versus physical therapy for a meniscal tear and osteoarthritis. N Engl J Med (2013) 6.08

A randomized study of how physicians interpret research funding disclosures. N Engl J Med (2012) 5.47

Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 5.25

Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 5.13

Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med (2014) 4.99

Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95

Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA (2011) 4.73

Self-management education programs in chronic disease: a systematic review and methodological critique of the literature. Arch Intern Med (2004) 4.68

Full coverage for preventive medications after myocardial infarction. N Engl J Med (2011) 4.51

The comparative safety of analgesics in older adults with arthritis. Arch Intern Med (2010) 4.47

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet (2012) 4.46

Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 4.40

Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation (2010) 4.37

New FDA breakthrough-drug category--implications for patients. N Engl J Med (2014) 4.30

Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst (2002) 4.16

Telephone screening, outreach, and care management for depressed workers and impact on clinical and work productivity outcomes: a randomized controlled trial. JAMA (2007) 4.11

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07

Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med (2002) 4.07

Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses' Health Study. J Am Coll Cardiol (2009) 3.99

A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol (2011) 3.98

Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA (2010) 3.85

Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. Arch Intern Med (2009) 3.84

Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol (2007) 3.82

The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med (2010) 3.78

The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med (2006) 3.64

Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med (2014) 3.62

Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA (2011) 3.58

Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology (2006) 3.54

Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ (2013) 3.43

The quality of pharmacologic care for vulnerable older patients. Ann Intern Med (2004) 3.34

Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol (2005) 3.33

The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med (2011) 3.27

Rethinking the use of physicians as hired expert lecturers. Ann Intern Med (2014) 3.22

Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. Eur Heart J (2007) 3.21

Drug-review deadlines and safety problems. N Engl J Med (2008) 3.16

Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med (2013) 3.13

Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation (2009) 3.09

Balancing innovation, access, and profits--market exclusivity for biologics. N Engl J Med (2009) 3.08

Incentives for drug development--the curious case of colchicine. N Engl J Med (2010) 3.06

Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.04

High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation (2013) 3.03

Confounding control in healthcare database research: challenges and potential approaches. Med Care (2010) 3.01

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation (2004) 2.98

University-based science and biotechnology products: defining the boundaries of intellectual property. JAMA (2005) 2.95

Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol (2010) 2.93

Compliance with osteoporosis medications. Arch Intern Med (2005) 2.91

Development of classification and response criteria for rheumatic diseases. Arthritis Rheum (2006) 2.88

A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum (2010) 2.88

Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med (2002) 2.85

Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med (2002) 2.82

Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol (2006) 2.81

Internet marketing of herbal products. JAMA (2003) 2.77

Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA (2004) 2.77

Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. Am J Epidemiol (2010) 2.74

Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation (2003) 2.73

The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med (2010) 2.71

Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA (2010) 2.71

Sending pharma better signals. Science (2005) 2.69

Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis (2005) 2.65

Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res (2003) 2.65

Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA (2011) 2.60

Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol (2008) 2.58

Excess weight and the risk of incident coronary heart disease among men and women. Obesity (Silver Spring) (2009) 2.56

Performance of propensity score calibration--a simulation study. Am J Epidemiol (2007) 2.56